SLC5A2 and chronic kidney disease: Among the broader comparison with SGLT2 inhibitors and GLP-1 receptor agonists, finerenone ranked among the agents with the lowest incidence of urinary-tract infection, highlighting its tolerability in patients with CKD [79].